Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Total revenues	$ 0	$ 0
Total cost of revenue	0	0
Gross profit (loss)	0	0
Research and development expense	1,943,000	1,645,000
Selling, general and administrative expense	1,870,000	1,639,000
Operating loss	(3,857,000)	(2,981,000)
Other income (expense):
Warrant revaluation income (expense)	(29,000)	235,000
Derivative revaluation income (expense)	55,000	(63,000)
Interest expense	(197,000)	(190,000)
Other income, net	362,000	98,000
Loss before income taxes	(3,666,000)	(2,901,000)
Income taxes	0	0
Net loss	(3,666,000)	(2,901,000)
Dividend paid in-kind to preferred stockholders	(85,000)	(82,000)
Deemed dividend on preferred stock (see Note 11)	(140,000)	(121,000)
Net loss attributable to common stockholders	$ (3,891,000)	$ (3,104,000)
Net loss:
Basic (usd per share)	$ (0.40)	$ (0.55)
Diluted (usd per share)	$ (0.40)	$ (0.55)
Weighted average number of common shares outstanding:
Basic (shares)	9,758,332	5,672,976
Diluted (shares)	9,758,332	5,672,976
Affiliated Entity
Research and development expense	$ 44,000	$ (303,000)